AstraZeneca’s long-acting antibody combination treats and prevents COVID-19
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca's AZD7442, a long-acting antibody (LAAB) combination, achieved a statistically...
Chemotherapy drug derived from fungus shows promise
Oxford University researchers have collaborated with biopharmaceutical company NuCana to assess a novel chemotherapy drug derived from a fungus. The results of a study published...
The Royal College of Psychiatrists calls for 7,000 more medical school places to meet...
The Royal College of Psychiatrists 2021 census has revealed that record numbers of people need mental health treatment but there aren’t enough psychiatrists to...
MHRA authorises Koselugo for children aged 3 years and above with neurofibromatosis type 1
AstraZeneca and MSD’s Koselugo®▼(Selumetinib) has been granted Conditional Marketing Authorisation in Great Britain by the Medicines & Healthcare products Regulatory Agency (MHRA) as monotherapy...
WHO recommends widespread rollout of GSK’s malaria vaccine
The World Health Organization (WHO) has recommended the wider use of GlaxoSmithKline’s (GSK’s) RTS,S malaria vaccine in children living in sub-Saharan Africa and other...
AiPharma and Appili Therapeutics form strategic alliance
Appili Therapeutics, the biopharmaceutical company focused on drug development for infectious diseases, and AiPharma have announced a strategic alliance to advance the global development...
NICE recommends first sickle cell disease treatment in two decades
The National Institute for Health and Care Excellence (NICE) has recommended that a new therapy for sickle cell disease is made available on the...
MSD announces its antiviral COVID-19 pill halves hospitalisations and deaths
MSD and Biotherapeutics have announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death in at...
Theramex launches first body-identical combined hormone therapy treatment
Theramex has launched Bijuva® (known as Bijuve® in the UK) across Europe and the UK. It is the first, and only, body-identical hormone therapy...
NICE recommends Roche’s atezolizumab as treatment for advanced bladder cancer
The National Institute of Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) for the use of Tecentriq®▼(atezolizumab) as a monotherapy...
Latest articles
Enter today! The Pf Awards 2022 are officially open
New Year | New Suite of Categories | New Candidates
Would you like to be recognised as a top performer in the UK Pharmaceutical industry? Enter...
New study to explore if talazoparib could treat metastatic breast cancer
A new study funded by Breast Cancer Now will explore if the drug talazoparib (Talzenna) could be used to treat people with incurable secondary...
£250m winter access fund for GPs to boost face to face appointments
The NHS has published a blueprint for improving access to GP appointments for patients alongside supporting GPs and their teams. Surgeries will be provided with additional funding...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Pancreatic Cancer Story: James Dadge
James, 44, lives in Manchester with his partner Andrea and sons Ben and Daniel. He was diagnosed with a neuroendocrine tumour, with the primary...
Adapting for success: Understanding commercial optimisation
How do you best align your field force with the changing landscape within the NHS? Oli Hudson, Content Director at Wilmington Healthcare, outlines the...
Positive SMC decision for first long-acting injectable HIV treatment
ViiV Healthcare has announced that the Scottish Medicines Consortium (SMC) has accepted Vocabria▼ (cabotegravir long-acting injection) in combination with Rekambys▼ (rilpivirine long-acting injection) for...
A CLASS DIVIDED – A LIFE CHANGING EXPERIMENT
What can your team learn about positive thinking from a schoolteacher in the 1970s and a world heavy weight champion? Ama Verdi-Ashton explains. It...